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Abstract Tri-modality PET/CT–MRI includes the transfer
of the patient on a dedicated shuttle from one system into
the other. Advantages of this system include a true
CT-based attenuation correction, reliable PET-quantification
and higher flexibility in patient throughput on both sys-
tems. Comparative studies of PET/MRI versus PET/CT are
readily accomplished without repeated PET with a differ-
ent PET scanner at a different time point. Additionally,
there is a higher imaging flexibility based on the avail-
ability of three imaging modalities, which can be combined
for the characterization of the disease. The downside is a
somewhat higher radiation dose of up to 3 mSv with a low
dose CT based on the CT-component, longer acquisition
times and potential misalignment between the imaging
components. Overall, the tri-modality PET/CT–MR system
offers comparative studies using the three different imag-
ing modalities in the same patient virtually at the same
time, and may help to develop reliable attenuation algo-
rithms at the same time.
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Introduction of the specific concept of PET/CT–MRI
Integrated positron emission tomography (PET)/computed
tomography (CT) has evolved into one of the major
imaging procedures in oncology imaging and partly also in
infection imaging.
However, PET/CT has several—technical as well as
diagnostic—limitations. Thus, there is increasing interest
in integrating PET with other imaging procedures like
magnetic resonance imaging (MRI) [1–3]. Superior soft
tissue contrast of MRI compared to CT and lower radiation
exposure are the most obvious advantages. However, there
are several technical and clinical challenges that have to be
resolved before CT can be replaced with MRI in such a
multimodal system. The current approach used in our
hospital is a sequential PET/CT-MRI system composed of
two major components: a 3T MRI system (Discovery 750w
3T, GE Healthcare, Waukesha, WI, USA) and a state-
of-the-art TOF PET/CT (Time of flight, Discovery 690, GE
Healthcare, Waukesha, WI, USA). Both systems can be
connected with a dedicated shuttle system (see ‘‘Technical
considerations,’’ Fig. 1a, b) which is based on a transfer-
able board mounted onto a mobile shuttle system that links
with the PET/CT and MRI from one side of the patient
handling system via a floor-mounted docking station. The
patient is first positioned on the transfer board on the fixed
MRI table and subsequently, the MRI is performed. In
order to limit the overall examination time for the patient,
the MRI is performed during the uptake period of the PET
tracer prior to the PET/CT examination. Following the
acquisition of the MRI, the patient is transferred on the
board to the shuttle system and redirected to the PET/CT.
The shuttle system docks to the floor-mounted rails and the
board is fitted on top of the PET/CT patient bed. Once
the patient is moved and positioned inside the gantry, the
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PET/CT examination commences. The PET/CT study is
performed with CT-based AC for PET-corrections in
clinical routine. The acquired PET/CT and the MRI are
retrospectively coregistered on a commercially available
imaging workstation (Advantage Windows, GE Health-
care). Images can be displayed as PET/CT, PET–MRI,
CT-only or PET-only. We always coregister the PET/CT
with the MRI data. The MRI examination is typically
performed as a whole-body examination due to current
research trials comparing PET/CT and PET–MRI, or as a
partial-body contrast-enhanced examination in the area of
interest (head/neck, abdomen, pelvis, brain, see below for a
more detailed discussion).
This paper will highlight some of the major issues and/
or advantages of introducing this new hybrid technology
into clinical routine, especially the advantages and disad-
vantages of simultaneous versus sequential PET/CT–MRI
and PET/MRI, the related technical issues, as well as
several research aspects which might arise in PET/CT–MR
and PET/MR.
Advantages and disadvantages of sequential
PET/CT–MR and simultaneous PET/MR
Several issues have to be addressed when evaluating a
sequential PET/CT–MR versus the simultaneous PET/MRI
approach. In our opinion, at the present state of the
development of PET/MR technology, the advantages of a
sequential PET/CT–MRI system outweigh the disadvan-
tages. Currently there are only very few data available in
the literature which demonstrate a potential advantage of
PET/MRI over PET/CT in routine clinical oncological
applications [1, 4–7]. So far, the majority of available
data does not find statistically significant advantages of
PET/MRI versus PET/CT concerning staging accuracy or
detection of distant metastases [8–11]. One clear advantage
of a sequential system is the flexibility in a routine clinical
environment. Since both scanners can be operated sepa-
rately, clinical PET/CT and MRI can be acquired at the
same time in different patients. With the dedicated shuttle
system, the patient can be shuttled back and forth between
both systems. An overview over possible protocols in a
clinical setting is given in Fig. 2.
Another key issue is how to achieve MRI-based atten-
uation correction (AC) and how to do adequate lung
imaging in MR. Currently there are different approaches on
how to perform MRI-based AC, e.g., template-based, atlas-
based/pseudo-CT [12]. The first results of MR-based AC of
PET-data using ultrashort echo time (UTE) sequences are
promising, but to date are very time consuming, especially
in large FOVs [13]. Another drawback in MR imaging is
the difficulty of lesion detection in body regions presenting
with large susceptibility changes, especially in the lung.
Although MRI can be performed with gated sequences,
those typically increase the acquisition time. Initial results
with fast breath hold GRE-sequences may offer sufficient
results in several cases [14, 15].
The development of an appropriate workflow for a PET/
CT–MRI system as well as for a simultaneous PET/MRI
remains challenging. Typically, whole-body PET/CT can
be done in 10–15 min while a diagnostic MR of even a
limited body region typically takes 25 min or more. Thus, a
possible approach to an adequate and timely workflow
might be similar to that of PET/CT, where a whole-body,
low-dose scan is followed by a regionally focused full
diagnostic CT. In PET/MRI, such a protocol would consist
of a quick wholebody overview (e.g., possibly with a
Dixon T1 GRE sequence) and a dedicated contrast-
enhanced MRI in the region of interest. However, a major
task for the future will remain the development of faster
and more robust sequences to be used in PET/CT–MRI and
combined PET/MRI.
Radiation issues have to be addressed when discussing the
sequential PET/CT–MR solution. In principle, there is cur-
rently a clear advantage concerning radiation dose in
simultaneous PET/MR systems because there is no addi-
tional CT-component. However, as long as the attenuation
correction issues are not solved, this argument is moot
[16–18]. Furthermore, much effort is applied to dose
reduction in CT and PET/CT. Model based iterative recon-
struction algorithms (MBIR) are already available in current
commercially available scanners and upcoming advanced
algorithms will reduce the CT dose even further. Thus, there is
considerable potential that the radiation dose from PET/CT–
MRI will be reduced by several factors in the near future.
One clear disadvantage of a sequential PET/CT–MR
solution is the total scanning time for the patients because,
no matter how short the MRI protocol might be, it is
always an add-on to the PET/CT-examination. Although
the overall patient stay time of PET/CT–MR might be the
same in case the MRI is done during uptake time, patients
might consider the ‘‘double-examination’’ as an extra
burden. On the other hand, only the sequential solution
currently offers the possibility to scan patients in a wide-
bore MRI, which is more comfortable for claustrophobic
and overweight patients. The lack of simultaneity is
another disadvantage. Simultaneity can be important in
interesting research applications such as dual neuro-acti-
vation or mapping studies or cardiac perfusion validation
studies. Since nuclear imaging is usually done in a pseudo-
steady-state tracer distribution, the meaning of simultaneity
is currently unclear in such measurements. Although this
approach (in neuro-imaging) currently does not have a
relevant application in clinical routine, this might change
with the installation of more simultaneous systems.
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Fig. 1 a Top row Side-loading
shuttle system in frontal view
(left) and top view (right)
consisting of a metal trolley
with counter balance weights
(60 kg) on each side (colored in
green) and two arms (colored in
blue) holding the glass fiber
board (colored in red). The
patient board can flexibly be slid
either to the right or the left of
the shuttle system, which
permits loading the patient onto
a scanner table from either side.
Bottom row 3D schematic of the
axial, front-loading patient
transporter docked to the
PET/CT table (left). When
connected, the rail-guided
transfer board (right) can easily
be slid between the shuttle and
the scanner. b Current design
concept with a 3T MRI system
and a TOF-PET/CT in two
rooms directly adjacent to each
other. The explanation of the
shuttle mechanism and
workflow is given in the
‘‘Introduction’’
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A significant disadvantage of current simultaneous
PET/MRI in clinical routine is in MR lung imaging. Here, CT
is still the best modality for nodule detection, evaluation of
parenchymal texture, speed and robustness. Due to signif-
icantly longer imaging time, even with breath hold GRE-
sequences, MRI has never matched the detection rates of
CT. In a recent study from our group there is still a higher
lesion detection rate in CT based on a lesion-by-lesion
evaluation when compared to breath hold GRE Lava Flex
T1 imaging, even when using the low-dose, limited axial
resolution CT-component from routine PET/CT with tidal
breathing [19]. However, in patient-based analysis, no
statistically significant difference was seen in this pre-
liminary study.
The current costs for simultaneous and sequential PET/
MRI systems (one-room solutions) are approximately 5
millions euros (in Europe). The costs for the tri-modality
system are comprised of the prize for a PET/CT, a MRI and
the dedicated shuttle solutions. Thus, depending on the
chosen components, we estimate that the total cost will be
between €3.5–5 million, depending on the system config-
uration. Those costs do not include (in any case) the costs
for staffing, floor space and service. The costs for the
procedure are comparable as well, of course depending on
the local circumstances (supply costs, reimbursement).
Technical considerations: patient transporter system
Multimodal imaging using separate, stand-alone PET/CT
and MR scanners is based on the critical assumption of
accurate multimodal image registration. Patient shuttle
systems have been developed to avoid patient repositioning
and minimize associated image misregistration, as well as
to improve the overall workflow. Such a patient transporter
system virtually connects the independent PET/CT and MR
scanners into a single, sequential tri-modality PET/CT–MR
imaging platform.
Conceptually, overall image misregistration can be
decomposed into hardware and patient-induced errors. The
former depends on the actual implementation of the shuttle
system and its mechanical tolerances. Because of the
rigidity of the patient shuttle, hardware registration errors
can, to a good approximation, be described via rigid
transformations. In comparison, patient-induced misregis-
tration is of non-rigid nature, is dependent on patient
Fig. 2 Overview over possible PET/CT–MRI protocols. For whole-
body (WB) indications, PET/CT with additional basic whole body
MRI might be applied (grey column). In more specific indications or
diseases, contrast-enhanced MRI confined to the area of interest might
be applied (partial body, PB) (blue column). For example, PET/CT
can be done as a whole-body examination and the following (full
diagnostic) MRI can be acquired, confined to the area of interest.
Alternatively, the MRI can be acquired first in the desired area of
interest (or whole body) during the uptake times. This concept holds
the advantage of not prolonging the total examination time since the
patient has to wait anyway (at least for most 18F tracers) for
approximately 1 h during the uptake period prior to PET. Imaging
times given in the figure are scan acquisition times and may vary
based on the medical status of the patient and ability to cooperate. The
protocols given here are examples and are not a complete overview,
as there are deviations of those protocols depending on the indication
and clinical question
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condition, anxiety and comfort, and tends to increase with
increasing time span between the individual scans. Accu-
rate and reproducible laser landmarking of the patient on
both scanners practically eliminates registration errors
along the axial direction. Misregistration along the lateral
direction can be minimized via accurate table height
adjustment (anterior–posterior direction) and guidance
mechanisms (left–right direction).
In a recent patient study, the mean offset between
PET/CT and MR was assessed to be well below 1 cm [20].
Image registration can be further refined via a subsequent
software registration step available on dedicated multi-
modal image viewing platforms, lsuch as the Advantage
Workstation (GE Healthcare, Waukesha, WI, USA) that
we used. Assuming accurate geometric calibration of the
PET/CT, image registration is most naturally done by
registering the MR data towards the CT.
In collaboration with industrial partners, two prototype
patient shuttles have been developed: (1) a lateral side-
loading shuttle and (2) an axial front-loading shuttle, both
depicted in Fig. 1a. The custom-built side-loading shuttle
(Fig. 1a, top row) was developed in collaboration with
a prototype engineering company (Innovation Design
Center, Thalwil, Switzerland) and consists of a metal
trolley and fiberglass transport board (colored in red). The
board carrying the patient is held by two supporting sliding
arms (colored in blue) and can flexibly be slid either to the
left or to the right. After sliding the board over the scanner
table, the table is elevated until the board is entirely sup-
ported. Subsequently, the board is released from the arms.
After image acquisition, the shuttle is again positioned next
to the scanner table and the arms are slid underneath the
transport board. By lowering the scanner table, the patient
is transferred back onto the shuttle and to the other side to
the undocked MRI table. The board with the patient is then
released.
There is also the possibility of using an axial front-
loading shuttle prototype (Fig. 1b). However, this was used
in a first trial phase, and currently only the side-loading
shuttle is used.
Technical considerations: quantification
in PET/CT–MR versus PET/MR
PET/MR imaging is still at an early phase of development,
with one of the key issues being PET quantification; in
particular the correction of attenuation- and scatter-induced
signal variations and artifacts and, to a lesser extent,
standard calibration and quality control measurements [21].
In PET/MR imaging, the PET attenuation information has
to be derived from the MR data. This is challenging
because unlike CT, MR data is not easily transformed into
PET attenuation maps. Solid materials like bones and RF
coils, the relative nature of MR signal, spatial signal vari-
ations induced by RF shading, and truncation artifacts due
to MR field-of-view limitations, which is typically below
50 cm, all cause problems. A number of MR-based PET
attenuation correction strategies have been developed,
especially: the segmentation of MR images into discrete
tissue classes (e.g., background/air, lung, fat and water-
based tissue) with corresponding assignment of average
PET attenuation values [22], atlas or template registration
to account for more tissue classes, especially bone and/or
RF coils [23–25], ultra-short TE-based MR imaging
methods for direct bone depiction [13, 26], as well as
maximum-likelihood methods for simultaneous estimation
of activity and attenuation from PET data only [27]. These
methods all have their strengths and weaknesses depending
on the anatomy of interest. For whole-body coverage,
including the head and RF coils, typically a combined
approach has to be used.
Obviously, in tri-modality PET/CT–MR the standard
CT-based PET attenuation correction can be used, which is
an important advantage in terms of accurate and robust
PET quantification. Furthermore, the sequential approach
allows selective presence of RF coils during MR scanning
and as well as their removal during PET/CT scanning
without moving the patient. This is an important advantage
considering that bulky RF head coil structures can cause
significant attenuation artifacts with loss of intrinsic count
rate of up to 50 % [26]. To avoid repositioning of the
patient during the selective placement or removal of RF
coils, the posterior coils ideally need to be integrated into
the MR scanner table. Similarly, for the head coil a dedi-
cated head holder is required which tightly fits into the coil
structure. Flexible anterior coils can easily be removed
from the patient.
In effect, the tri-modality PET/CT–MR system can use
standard CT-based PET attenuation correction and it can
effectively be used for the development and evaluation of
MR-based PET attenuation correction methods as well
as for clinical evaluation of PET/CT versus PET–MR
[28, 29].
Clinical motivation, clinical experience and objectives
The clinical motivation for PET/CT–MRI and simulta-
neous PET/MRI is based on the observation that in several
clinical oncological indications the value of PET/CT is
limited. Generally N-staging and M-staging is not impaired
but it can be difficult to assess different tumor entities with
regard to T-staging. This is based on the PET/CT’s intrinsic
lower soft tissue contrast compared to high-resolution
MRI, even with state-of-the art CT-components.
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In whole-body applications, such as for lymphoma,
several publications compared PET/CT with MRI [30].
There are conflicting results in the literature concerning the
agreement of DWI–MRI and PET/CT [31, 32]. DWI–MRI
within PET/MRI holds the advantage of using a lower
radiation dose when compared to PET/CT–MRI. However,
because DWI–MRI currently does not match the diagnostic
accuracy of PET/CT, a sophisticated imaging concept
would be for example, having a PET/MRI for initial
staging and DWI–MRI for follow-up because several
papers point out this as a strength of DWI. Other whole-
body indications are myeloma and melanoma. In multiple
myeloma, PET/CT currently is considered the gold stan-
dard for therapy follow-up in this specific patient popula-
tion. WB–MRI on the other hand is able to visualize
especially lytic bone marrow lesions much better than CT,
while CT has advantages in the detection of cortical
lesions. Thus, PET/CT–MRI might provide useful con-
current information in myeloma patients, especially in
therapy follow-up settings where the PET-component can
be negative [33, 34]. In melanoma patients it has already
been proven in multiple publications that MRI is superior
to FDG-PET/CT in detection and characterization of brain
metastases [35, 36]. However, it is well known that FDG-
PET/CT is not well suited for detection of brain metastases.
Here, 18F-FET or 11C-methionin are examples of much
better tracers for brain tumors, and PET and comparisons
with MRI should be done using these tracers.
Several publications also investigated the superiority of
MRI versus 18F-FDG PET/CT in liver lesions, and only
very few so far have compared PET/CT and PET–MRI
[37]. This is mainly based on the high background activity
of the liver in PET and the intrinsic lower soft-tissue
contrast provided by CT compared to MRI. Admittedly,
very few studies actually compare cePET/CT (contrast—
enhanced PET/CT) with MR for this purpose. However, a
large meta-analysis showed that MRI and 18F-FDG/CT are
not statistically significantly different in lesion detection
[38]. Our own experience in an initial comparison of
cePET/CT versus non cePET-MRI showed that (based on the
PET-component) all lesions within the liver were detected
on both multimodal imaging methods. However, lesion
conspicuity was significantly better on the MRI component
evaluated within a PET/CT–MRI system when compared
to the ceCT component, especially when using T1 and T2
sequences [7] (Fig. 3). Additionally, when comparing
the standard low-dose PET/CT versus PET–MRI in liver
lesions, lesion conspicuity was again significantly better on
PET–MRI when read by two independent readers. Lastly,
several liver metastases (e.g., from uveal melanoma,
Fig. 3 Enhanced lesion detection with contrast-enhanced
PET/CT ? MRI in liver lesions. Patient with metastasizing colon
cancer with a focal 18F-FDG-positive liver lesion in the left liver
lobe, barely seen on the ceCT-component. Top row PET (a), ceCT
(b), PET/CT (c). Lesion conspicuity is significantly higher on non-
contrast-enhanced T1 (d) and FIESTA (e). No difference in lesion
detection is noted when compared between PET/CT (c) and PET/MRI
(f)
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metastases after therapy) as well as the majority of primary
liver tumors can be FDG-negative in a significant number
of patients [39]. Although there is currently no study
available focusing on those patient groups, it is very clear
that patients will benefit from the additional MRI within a
PET/CT–MRI setting.
Two other abdominal indications will benefit from PET/
CT–MRI. Diagnosis of neuroendocrine tumors (NET) of
the gastrointestinal tract has been recently changed
dramatically with the introduction of new tracers like
18F-DOPA or 68-Ga DOTA (TATE/TOC/NOC) into
clinical routine [40–42]. The new NET-specific tracer
based PET/CT has proven to be superior to all other
imaging modalities available. Since NET of the GI-tract
are typically very small lesions within the bowel wall with
adjacent larger mesenteric lymph nodes, this indication
will probably also benefit from a PET/CT–MRI approach.
A similar reasoning may apply for gastrointestinal
infection imaging with PET/MRI, e.g., in Crohn’s disease.
MRI has become the main imaging modality used to image
and evaluate affected bowel parts, and dynamic MRI is
able to evaluate hypo-/akinetic sections and concurrent
inflammatory activity [43, 44]. On the other hand, PET/CT
already has proven to be a highly accurate imaging
modality in low-grade infections [45–47]. Thus, the com-
bination of both procedures might be beneficial by making
it possible to arrive at a more exact diagnosis in determi-
nation of active versus inactive inflammatory lesions.
There are clear advantages of MRI compared to CT in
anatomically challenging areas like the pelvis. Prostate
imaging serves as a good example where the technical
capabilities of MRI (e.g., DWI–MRI, spectroscopy) are
able to differentiate tumor from prostate tissue, which is
not possible with contrast-enhanced CT. 18F-and 11C-
Choline-PET/CT on the other hand has become the main-
stay in the restaging of prostate cancer patients, while
primary staging is only conducted in high risk patients [48,
49]. The combination of PET/CT–MRI can serve in those
cases as a one-stop-shop imaging tool, providing infor-
mation about the local tumor status, the nodal status and
distant metastases. While there is no simultaneity needed
for the restaging scenario, primary staging might be a well
suited indication for simultaneous PET/MRI because
prostate MRI is frequently done with an endorectal coil.
Another area with advantages for PET/MRI will be head
and neck cancer. In particular, the infiltration of tumors in
surrounding tissues can be visualized with MRI in an
unparalleled way, which is partly not achievable by con-
trast-enhanced CT. PET/CT has been proven superior in
the detection of lymph node metastases based on the PET-
component, when compared to morphological imaging
modalities [50]. Hence, PET/CT and MRI are currently the
staging tools of choice for surgical as well as radiotherapy
planning. Since both procedures are often performed for
head and neck cancer, a combined PET/CT–MRI approach
seems advantageous. The combination of PET/CT–MRI
also has advantages in patients with metal artifacts in CT,
as new MR sequences can minimize those artifacts. Thus,
head and neck cancer is certainly one of the most prom-
ising indications for a PET/CT–MRI or simultaneous
PET/MRI.
In neuroimaging, MR images are often a prerequisite for
the processing and analysis of PET data. The morphology
depicted by MR imaging helps to correctly interpret 18F-
FET (Fluoro-ethyl-tyrosine) PET images in brain tumor
patients, to evaluate potential cofactors in Alzheimer’s
disease, to allow for normalization of PET data into ste-
reotactic space and hence automated image analysis, and to
correct the PET data for partial volume effects. Quantita-
tive analysis of brain pathologies is of major importance
for the standardization of treatment and therapy assess-
ment. PET is widely accepted as a reliable tool for the
quantification of pathological processes, but MRI also
offers a wide range of advanced techniques for quantitative
imaging [51, 52], such as apparent diffusion coefficient
(ADC) maps as a tool for the quantification of cellular
density [53], arterial spin labeling (ASL) for measurements
of blood flow [54], and dynamic contrast-enhancement
(DCE) to assess the characteristics of tumor vasculature,
including perfusion, blood vessel permeability, blood vol-
ume and extravascular extracellular volume fraction [55].
Therefore, the combination of PET and MRI has the
potential to become a powerful tool for quantitative
imaging and objective decision making. As the skull is a
rigid object, reliable coregistration of PET and MR data is
possible also from different imaging devices. Hence, inte-
grated PET/MRI in this setting is likely ‘‘nice to have’’
but often not mandatory in clinical multiparametric
neuroimaging.
Perspective on clinical use in future and research
perspectives
Concerning the value of PET–MR in terms of clinical use
and utility, we are currently in favor of the tri-modality
solution. It offers the possibility to compare PET/CT and
PET–MRI in a clinical routine setting and an easy way to
acquire patients for comparison trials. The MRI can be
done during the uptake time without major restrictions
concerning scan time—which is the case when MRI-
sequences have to be adapted to the bed-positions in PET.
The patient can be transferred with an aforementioned
dedicated shuttle system to PET/CT. In this way, no dif-
ferences in SUV between the first (or second) PET from
PET/CT and the second (or first) PET from simultaneous
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PET/MRI limit interpretation of data and quantification,
and the comparison between follow-up studies is straight
forward. A second unparalleled advantage is that PET/CT
and MRI can be used as independent imaging modalities as
discussed above.
Future indications used in clinical routine are primarily
the above-mentioned oncological indications, where the
additional MRI-component in addition to PET/CT offers
important information for diagnosis, surgical or RT-plan-
ning. This is especially useful in head and neck cancer,
liver lesion characterization and localization, pelvic tumors
including prostate cancer, and neuroendocrine tumors. Also
this multimodal imaging will have a role in inflammatory
and infection-imaging.
Our primary goal in clinical neuroimaging is to combine
quantitative PET and MR imaging and to establish this
multimodal procedure in routine imaging of brain pathol-
ogies. To accomplish this goal, the PET–MR examination
has to be integrated in a sequential or simultaneous imag-
ing system. Only a locally and temporally combined
examination permits that PET/MRI is perceived as a
simultaneous entity by the patient and the referring phy-
sician. Therefore, PET/MRI as well as PET–MR imaging
protocols have been established, combining MRI with
different PET-tracers such as 18F-FET for brain tumors,
Ga68-DOTATATE for therapy evaluation in meningioma
patients, 18F-DOPA and C11-Raclopride for characteriza-
tion of movement disorders, C11-Pittsburgh compound B
as well as 18F-FDG in Alzheimer’s disease or other neu-
rodegenerative disorders, and O15-H2O for cerebrovascu-
lar diseases (Fig. 4).
There are several research perspectives for a PET/CT–
MRI system, which are not accessible by a simultaneous
system, and vice versa. One example is multiparametric
imaging which integrates information from different
modalities into one value or diagnosis, an approach which
is increasingly gaining interest. Multiple options are pos-
sible with a sequential system: the integration of CT-per-
fusion into PET/CT has already been accomplished in
several trials and has proven in part to provide additional
information on the glycolytic state of the tumor [56, 57].
The PET/CT–MRI system now offers the possibility to
acquire PET/CT with integrated CT-perfusion and addi-
tional MRI-perfusion data with a negligible time gap and
good coregistration. Thus, generally such a tri-modal sys-
tem offers the possibility of integration of more modalities
than a simultaneous system—however, for the price of
non-simultaneity.
Even non-contrast-enhanced perfusion sequences (ASL,
arterial spin labeling) [58, 59] can be acquired, compared,
and possibly integrated for several body oncology and
neuroradiological indications in the near future. One major
task will be the adaption of MRI-sequences within
PET/CT–MRI and simultaneous PET/MRI to the PET-emission
time and the PET-FOV. Current MRI-protocols—espe-
cially for whole body—as well as neuro-applications are
not well suited, based on their rather long examination
times.
Conclusion
PET/CT–MRI is currently a valuable tool for investigating
the value of adding MRI rather than CT to PET in clinical
routine and offers the added value of clinical flexibility due
to the two-room, tri-modal concept. This way, the selected
indications discussed above, in which a simultaneous
PET/MRI is possibly needed, can be evaluated and and the
value of these modalities established for clinical routine. The
costs for a tri-modal system are generally comparable to a
Fig. 4 In cerebrovascular pathologies, a combined approach with MRI, MR-angiography and quantitative PET perfusion measurement is helpful
in assessing the extent of the disease. From left to right: T2 weighted MRI, subtraction MR-angiography and O15-H2O PET
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simultaneous system, however, it offers more flexibility
concerning the choice of components. PET/CT–MRI, as
well as simultaneous PET/MRI offer major research pos-
sibilities in body as well as in neurological applications to
learn about tumor characteristics, evaluate new therapy
follow-up strategies, enhance patient comfort and reduce
radiation dose burden at the same time.
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